Cytokine and chemokine profiles following vaccination with human papillomavirus type 16 L1 virus-like particles

被引:29
作者
Garcia-Pineres, Alfonso
Hildesheim, Allan
Dodd, Lori
Kemp, Troy J.
Williams, Marcus
Harro, Clayton
Lowy, Douglas R.
Schiller, John T.
Pinto, Ligia A.
机构
[1] NCI Frederick, Frederick, MD 21702 USA
[2] SAIC Frederick Inc, HPV Immunol Lab, Frederick, MD USA
[3] Natl Inst Hlth, Div Canc Epidemiol & Genet, Bethesda, MD USA
[4] Natl Inst Hlth, Div Canc Treatment & Diagnosis, Biometr Res Branch, Bethesda, MD USA
[5] Johns Hopkins Univ, Baltimore, MD USA
[6] Natl Inst Hlth, Ctr Canc Res, Bethesda, MD USA
关键词
D O I
10.1128/CVI.00090-07
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
To determine the systemic cytokine pattern induced by vaccination with human papillomavirus (HPV) L1 virus-like particles (VLP), we analyzed 22 different cytokines in culture supernatants of Ll VLP-stimulated peripheral blood mononuclear cells from vaccine (n = 19) and placebo (n = 7) recipients at months 0 and 2 after vaccination, using a multiplex cytokine bead array. In vaccine recipients, incubation with Ll VLP in vitro led to a statistically significant increase in production of Th1 (granulocyte-macrophage colony-stimulating factor, interleukin-2 [IL-2], gamma interferon; P < 0.0007) and Th2 (IL-4, IL-5, IL-10, IL-13; P < 0.0017) cytokines and the chemokine IP-10 (P = 0.0021) at month 2 after immunization, compared to levels seen prior to vaccination. These responses were not seen in placebo recipients. Cytokine and neutralizing antibody responses to vaccination followed the same pattern, with the highest antibody responses seen for subjects with higher cytokine responses. Cytokine profiling studies using samples from efficacy trials may provide important information about discriminators of long-term protection against HPV.
引用
收藏
页码:984 / 989
页数:6
相关论文
共 29 条
[1]   Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine [J].
Brown, DR ;
Fife, KH ;
Wheeler, CM ;
Koutsky, LA ;
Lupinacci, LM ;
Railkar, R ;
Suhr, G ;
Barr, E ;
Dicello, A ;
Li, WL ;
Smith, JF ;
Tadesse, A ;
Jansen, KU .
VACCINE, 2004, 22 (21-22) :2936-2942
[2]   Physical interaction of human papillomavirus virus-like particles with immune cells [J].
Da Silva, DM ;
Velders, MP ;
Nieland, JD ;
Schiller, JT ;
Nickoloff, BJ ;
Kast, WM .
INTERNATIONAL IMMUNOLOGY, 2001, 13 (05) :633-641
[3]   Vaccination in humans generates broad T cell cytokine responses [J].
De Rosa, SC ;
Lu, FX ;
Yu, J ;
Perfetto, SP ;
Falloon, J ;
Moser, S ;
Evans, TG ;
Koup, R ;
Miller, CJ ;
Roederer, M .
JOURNAL OF IMMUNOLOGY, 2004, 173 (09) :5372-5380
[4]   Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine [J].
Emeny, RT ;
Wheeler, CM ;
Jansen, KU ;
Hunt, WC ;
Fu, TM ;
Smith, JF ;
MacMullen, S ;
Esser, MT ;
Paliard, X .
JOURNAL OF VIROLOGY, 2002, 76 (15) :7832-7842
[5]   A phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers [J].
Evans, TG ;
Bonnez, W ;
Rose, RC ;
Koenig, S ;
Demeter, L ;
Suzich, JA ;
O'Brien, D ;
Campbell, M ;
White, WI ;
Balsley, J ;
Reichman, RC .
JOURNAL OF INFECTIOUS DISEASES, 2001, 183 (10) :1485-1493
[6]  
Fausch SC, 2003, CANCER RES, V63, P3478
[7]   Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women [J].
Fife, KH ;
Wheeler, CM ;
Koutsky, LA ;
Barr, E ;
Brown, DR ;
Schiff, MA ;
Kiviat, NB ;
Jansen, KU ;
Barber, H ;
Smith, JF ;
Tadesse, A ;
Giacoletti, K ;
Smith, PR ;
Suhr, G ;
Johnson, DA .
VACCINE, 2004, 22 (21-22) :2943-2952
[8]   Role of DC-SIGN in the activation of dendritic cells by HPV-16 L1 virus-like particle vaccine [J].
García-Piñeres, AJ ;
Hildesheim, A ;
Trivett, M ;
Williams, M ;
Wu, L ;
KewalRamani, VN ;
Pinto, LA .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2006, 36 (02) :437-445
[9]   Sustained efficacy up to 4-5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial [J].
Harper, DM ;
Franco, EL ;
Wheeler, CM ;
Moscicki, AB ;
Romonowski, B ;
Roteli-Martins, CM ;
Jenkins, D ;
Schuind, A ;
Clemens, SAC ;
Dubin, G .
LANCET, 2006, 367 (9518) :1247-1255
[10]   Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine [J].
Harro, CD ;
Pang, YYS ;
Roden, RBS ;
Hildesheim, A ;
Wang, ZH ;
Reynolds, MJ ;
Mast, TC ;
Robinson, R ;
Murphy, BR ;
Karron, RA ;
Dillner, J ;
Schiller, JT ;
Lowy, DR .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (04) :284-292